Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott Goldsmith, Marcie Riches, Jennifer A. Kanakry et al.|Blood|2021Cited by 177
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Mary Eapen, Rizwan Romee et al.|Blood|2021Cited by 163
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remissionArmin Rashidi, Richard F. Olsson, Mehdi Hamadani et al.|Blood Advances|2019Cited by 128